Where is vivitide located?

vivitide is headquartered in Gardner, United States. It is registered at Gardner, Massachusetts.

How many employees does vivitide have?

As of Dec 31, 2021, vivitide has 94 employees, reflecting a 5% year-over-year growth in headcount.

Is vivitide a funded company?

vivitide is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does vivitide rank among its competitors?

vivitide ranks 10th amongst 65 active competitors, of which 8 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Enzene, which secured $50M in Jan, 2023.

Who are the top competitors of vivitide?

vivitide's top competitors include Enzene, Shaanxi Micot Technology and PolyPeptide. Among them, Enzene secured the most recent funding round in January, 2023.

vivitide - 2026 Company Profile, Funding & Competitors

vivitide is an acquired company based in Gardner (United States), founded in 1983. It operates as a Provider of drug development services for neoantigen peptide and antibody services. The company has 65 active competitors, including 8 funded and 9 that have exited. Its top competitors include companies like Enzene, Shaanxi Micot Technology and PolyPeptide.

Company Details

Website: vivitide.com
Social
Email ID: *****@vivitide.com
Phone Number: +1 **********
Registered Address: Gardner, Massachusetts

Key Metrics

Founded Year

1983

Location

Gardner, United States

Stage

Acquired

Investors

Ampersand Capital

Ranked

10^th among 65 active competitors

Employee Count

94 as on Dec 31, 2021

Similar Companies

Enzene & 72 more

Exit Details

Acquired by Biosynth Carbosynth (Mar 17, 2022)

View vivitide's full profile

vivitide is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
New England Peptide, Inc. CIN: 43450608 , United States, Active	Dec 31, 1999	-	123 (As on Dec 31, 2022)	-

vivitide got acquired by Biosynth Carbosynth on Mar 17, 2022.

Click here to take a look at vivitide's acquisition in detail

vivitide is a funded company. vivitide has 1 institutional investor.

View details of vivitide's funding rounds and investors

vivitide's employee count trend

vivitide has 94 employees as of Dec 21. The total employee count is 4.0% more than what it was in Dec 20. Here is vivitide's employee count trend over the years:

Uncover vivitide's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of vivitide include Enzene, Shaanxi Micot Technology and PolyPeptide. Here is the list of Top 10 competitors of vivitide, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Enzene 2015, Pune (India), Series C	Company specializing in development of Biosimilars	$50M	F-Prime Capital, Eight Roads Ventures & 1 others	55/100
2nd	Shaanxi Micot Technology 2007, China, Series B	Provider of drug research and development services focused on cardiovascular and metabolic diseases	$72.2M	NLVC, Tasly & 2 others	45/100
3rd	PolyPeptide 1952, Baar (Switzerland), Public	CMO manufacturing proprietary,GMP grade and non-GMP-grade peptides	-	-	45/100
4th	Hybio Pharmaceutical 1998, Shenzhen (China), Public	Developer and manufacturer of polypeptide drugs and APis	$15M	Shenzhen Capital Group, SAIF Partners & 1 others	43/100
5th	AmbioPharm 2006, North Augusta (United States), Series B	Peptide manufacturing and development services, setting a new standard worldwide	$24M	The Carlyle Group, MVM	42/100
6th	Custom Peptide Synthesis 2011, Mumbai (India), Unfunded	Manufacturer of peptides and other finished formulations, & APIs	-	-	40/100
7th	Proteos Biotech 2010, Madrid (Spain), Unfunded	Manufacturer of recombinant enzymes and provides CMO services	-	-	38/100
8th	Rameda 1994, Giza (Egypt), Public	Developer and manufacturer of generic pharmaceuticals, nutraceuticals, food supplements and veterinary products	-	Public Investment Fund, Compass Capital	37/100
9th	USV Peptides 2011, Mumbai (India), Unfunded	CDMO offering custom peptide, GMP peptide and cosmetic peptide synthesis services	-	-	34/100
10th	vivitide 1983, Gardner (United States), Acquired	Provider of drug development services for neoantigen peptide and antibody services	-	Ampersand Capital	32/100